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This article gives a personal view of some of 
the major unanswered research questions at 
the interface between bone and endocrinol-
ogy. One of the most compelling challenges 
relates to the emerging relationship between 
bone and energy metabolism. On a clini-
cal level, it is well established that obesity 
exerts a protective effect on bone mass and 
risk  of  osteoporosis,  an  influence  which 
appears  to  be  established  in  childhood 
(Tobias, 2010). In terms of explaining this 
relationship between fat and bone, a series 
of studies by Karsenty and colleagues based 
on transgenic mice identified an intriguing 
pathway linking bone turnover and energy 
metabolism involving decarboxylated oste-
ocalcin and insulin (Ferron et al., 2010). 
This finding is consistent with an inverse 
association between osteocalcin and insulin 
levels observed in elderly men (Kindblom 
et al., 2009). However, extraskeletal recep-
tors for osteocalcin responsible for mediat-
ing such a pathway are yet to be identified. 
Moreover, there may be fundamental differ-
ences in the regulation of energy metabo-
lism between man and rodent models, and 
in the absence of prospective clinical data 
linking changes in bone turnover to altera-
tions in glucose tolerance and/or fat mass, 
the relevance of this mechanism to humans 
remains unclear.
A  related  question  is  whether  bone 
metabolism is related to energy metabolism 
not only as a consequence of interactions 
with insulin, but also whether there is sig-
nificant interplay with endocrine pathways 
originating from the intestine. It has been 
recognized for some time that feeding causes 
rapid suppression of bone markers such as 
beta CTX (Clowes et al., 2002), presumably 
reflecting an influence of gut-derived hor-
mones on bone turnover. Intriguingly, fur-
ther recent work by Karsenty and colleagues 
suggests  that  gut-derived  hormones  also 
exert a profound influence on bone mass, 
based on their findings in transgenic mice 
which suggest that reduced production of 
serotonin by the gut underlies familial high 
bone mass in patients with mutations of 
the LRP5 gene (Yadav et al., 2008), which 
in turn suggests that serotonin antagonists 
represent a novel approach to treating oste-
oporosis (Yadav et al., 2010). However, the 
role of reduced serotonin levels in mediat-
ing this phenotype remains controversial, 
not the least because patients with carci-
noid syndrome, in whom circulating levels 
of serotonin are greatly increased, are not 
known to develop osteoporosis.
Dissecting out the mechanism of action 
of PTH, the major endocrine regulator of 
calcium metabolism, is a further impor-
tant challenge. Continuous and intermit-
tent exposure to PTH have diverse effects 
on bone, predominantly stimulating bone 
resorption  and  formation  respectively. 
There have been extensive studies to char-
acterize  the  intracellular  signaling  and 
downstream paracrine pathways involved 
in these actions (Datta and Abou-Samra, 
2009), in the hope that this will enable the 
development of new anabolic therapies for 
osteoporosis that unlike teriparatide (which 
shares the 1–34 n-terminal of PTH and is 
administered by daily sc injection) can be 
given orally. Several paracrine factors have 
being identified which are also involved in 
the local actions of PTH on bone, such as 
the RANK/RANKL/OPG system involved 
in  regulating  osteoclast  differentiation, 
and sclerostin which has been implicated 
in PTH-dependent effects on the osteob-
last lineage (Kramer et al., 2010). Assays 
for these paracrine factors have revealed 
the presence of significant levels in the cir-
culation, leading to the question of whether 
RANK, RANKL, OPG, and sclerostin repre-
sent endocrine regulators of bone in their 
own right. For example, recent studies sug-
gest that the protective effect of estrogen 
on bone mass is associated with alterations 
in circulating levels of sclerostin (Modder 
et al., 2010). However, it is difficult to infer 
causality from these studies, and whether 
systemic levels of these factors as distinct 
to their local levels in bone have any mean-
ingful regulatory role remains an important 
but as yet unanswered question.
A  further  interesting  challenge  is  to 
  dissect out the role of early life factors in 
bone  development.  There  is  intriguing 
evidence that early life factors particularly 
those operating in utero exert long term 
effects on subsequent growth and develop-
ment through a process known as program-
ming. Though most of this research has 
focused on relationships between in utero 
deprivation and outcomes related to other 
chronic conditions such as obesity, type II 
diabetes and heart disease, skeletal develop-
ment may also be affected. Precisely which 
in utero factors are most important in this 
regard remains unknown, but possibilities 
include maternal vitamin D status (Javaid 
et al., 2006), which if confirmed point to 
simple interventions in the mother which 
may have important long term effects on 
skeletal health of the child.
There are also exciting opportunities for 
applying recent methodological advances 
to  the  study  of  bone  endocrinology. 
Whereas the development of cloning and 
transgenic techniques nearly two decades 
ago led to major advances in elucidating a 
wide range of biological pathways, recent 
advances  in  genetic  epidemiology  have 
the potential to yield equally important 
insights. For example, genome wide asso-
ciation studies have not only confirmed 
associations between bone mineral density 
(BMD) and genetic markers in key bone 
regulatory genes such as OPG, RANK and 
RANKL, but have also identified an array 
of new genes involved in regulating bone 
mass (Rivadeneira et al., 2009). Individual 
genetic influences identified from these 
studies  have  been  relatively  small,  and 
the majority of heritability of bone mass 
remains to be explained. Identifying this 
‘missing heritability’ is a major challenge, 
and may depend on the study of rarer vari-
ants (requiring denser coverage of genome 
wide scans, application of whole genome 
sequencing  and  use  of  larger  cohorts) 
and parent of origin effects (necessitat-
ing  cohorts  with  DNA  from  successive 
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  burden due to osteoporotic fractures increas-
ing rapidly as a result of the aging population, 
the ultimate challenge will be to translate 
these insights into new therapies which are 
superior to those in current use in terms of 
effectiveness, tolerability, safety and cost.
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Genome-wide association meta-analysis for cortical 
Whereas  genetic  studies  in  bone  have 
largely  been  restricted  to  using  BMD  as 
measured by DXA as the main phenotypic 
outcome, this is a composite measure com-
bining several different characteristics includ-
ing  bone  size,  cortical  thickness,  cortical 
density and the amount of trabecular bone. 
Use of alternative techniques such as pQCT 
which provide separate measures of these 
constituents may enable new genetic influ-
ences on bone to be identified, as illustrated 
by our recent finding of an independent sig-
nal within the RANKL gene associated with 
cortical BMD (Paternoster et al., in press). 
Characterizing genetic influences on bone 
in more detail may be particularly informa-
tive in terms of identifying factors that affect 
bone fragility and risk of fracture, given the 
important contribution of such parameters 
to overall bone strength. Although pQCT 
has  limited  resolution,  newer  techniques 
like extreme CT provide the opportunity for 
dissecting out genetic influences on further 
characteristics such as cortical porosity and 
trabecular number which may have relatively 
strong predictive value for fracture.
In summary, bone endocrinology faces 
several important challenges including con-
firmation that the skeleton plays a physi-
ological  role  in  regulating  other  systems 
such as energy metabolism, and that local 
factors such as sclerostin serve as endocrine 
regulators of bone. Recent methodological 
advances in areas such as genetics and the 
assessment  of  bone  phenotypes  provide 
new important opportunities for addressing 
these and related questions. With the disease 